Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 640

1.

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.

Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Int Urol Nephrol. 2019 Sep 21. doi: 10.1007/s11255-019-02284-1. [Epub ahead of print]

PMID:
31542882
2.

Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues.

Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Möller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R.

Oncotarget. 2019 Sep 10;10(52):5439-5453. doi: 10.18632/oncotarget.27145. eCollection 2019 Sep 10.

3.

Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers.

Luebke AM, Attarchi-Tehrani A, Meiners J, Hube-Magg C, Lang DS, Kluth M, Tsourlakis MC, Minner S, Simon R, Sauter G, Büscheck F, Jacobsen F, Hinsch A, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Clauditz TS, Burandt E, Wilczak W, Höflmayer D.

Cancer Biol Med. 2019 May;16(2):319-330. doi: 10.20892/j.issn.2095-3941.2018.0384.

4.

Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H.

Knipper S, Beyer B, Mandel P, Tennstedt P, Tilki D, Steuber T, Graefen M.

World J Urol. 2019 Sep 11. doi: 10.1007/s00345-019-02950-0. [Epub ahead of print]

PMID:
31511970
5.

Comparison of intra- and postoperative analgesia and pain perception in robot-assisted vs. open radical prostatectomy.

Knipper S, Hagedorn M, Sadat-Khonsari M, Tian Z, Karakiewicz PI, Tilki D, Heinzer H, Michl U, Steuber T, von Breunig F, Zöllner C, Graefen M.

World J Urol. 2019 Sep 6. doi: 10.1007/s00345-019-02938-w. [Epub ahead of print]

PMID:
31493108
6.

Minimum Number of MRI Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective Lesion-Based Analyses of Patients Treated with Radical Prostatectomy.

Leyh-Bannurah SR, Kachanov M, Beyersdorff D, Tian Z, Karakiewicz PI, Tilki D, Fisch M, Maurer T, Graefen M, Budäus L.

J Urol. 2019 Sep 4:101097JU0000000000000527. doi: 10.1097/JU.0000000000000527. [Epub ahead of print]

PMID:
31483694
7.

Zweitlinientherapie beim metastasierten kastrationsrefraktären Prostatakarzinom (mCRPC).

Rexer H, Graefen M, Merseburger A.

Aktuelle Urol. 2019 Sep;50(5):478-479. doi: 10.1055/a-0901-9007. Epub 2019 Aug 29. German. No abstract available.

PMID:
31466095
8.

Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy.

Schroeder C, Navid-Hill E, Meiners J, Hube-Magg C, Kluth M, Makrypidi-Fraune G, Simon R, Büscheck F, Luebke AM, Goebel C, Lang DS, Weidemann S, Neubauer E, Hinsch A, Jacobsen F, Lebok P, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Sauter G, Höflmayer D.

Oncotarget. 2019 Aug 13;10(48):4973-4986. doi: 10.18632/oncotarget.27132. eCollection 2019 Aug 13.

9.

Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in D'Amico Intermediate- and High- Risk Radical Prostatectomy Patients: A Multi-Institutional Study.

Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, Taille A, Briganti A, Salomon L, Ploussard G, Tilki D; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).

J Urol. 2019 Aug 22:101097JU0000000000000504. doi: 10.1097/JU.0000000000000504. [Epub ahead of print]

PMID:
31437119
10.

A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer.

Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Jul 19. pii: S1558-7673(19)30224-1. doi: 10.1016/j.clgc.2019.07.008. [Epub ahead of print]

PMID:
31416752
11.

The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.

Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Eur Urol Oncol. 2019 Sep;2(5):541-548. doi: 10.1016/j.euo.2018.10.010. Epub 2018 Nov 22.

PMID:
31411992
12.

Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.

Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Oncol. 2019 Mar 28. pii: S2588-9311(19)30035-5. doi: 10.1016/j.euo.2019.03.003. [Epub ahead of print]

PMID:
31411975
13.

Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.

Minner S, Hager D, Steurer S, Höflmayer D, Tsourlakis MC, Möller-Koop C, Clauditz TS, Hube-Magg C, Luebke AM, Simon R, Sauter G, Göbel C, Weidemann S, Lebok P, Dum D, Fraune C, Izbicki J, Burandt E, Schlomm T, Huland H, Heinzer H, Haese A, Graefen M, Heumann A.

Neoplasia. 2019 Sep;21(9):872-881. doi: 10.1016/j.neo.2019.07.003. Epub 2019 Aug 2.

14.

Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer.

Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI.

Clin Genitourin Cancer. 2019 May 27. pii: S1558-7673(19)30160-0. doi: 10.1016/j.clgc.2019.05.022. [Epub ahead of print]

PMID:
31375352
15.

Impact of Obesity on Perioperative Outcomes at Robotic-assisted and Open Radical Prostatectomy: Results From the National Inpatient Sample.

Knipper S, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Urology. 2019 Jul 20. pii: S0090-4295(19)30646-6. doi: 10.1016/j.urology.2019.05.053. [Epub ahead of print]

PMID:
31336110
16.

The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.

Büscheck F, Zub M, Heumann A, Hube-Magg C, Simon R, Lang DS, Höflmayer D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Sauter G, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Clauditz TS, Burandt E, Wilczak W, Steurer S, Minner S.

Tumour Biol. 2019 Jul;41(7):1010428318824815. doi: 10.1177/1010428318824815.

PMID:
31296150
17.

Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.

Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M, Joniau TS, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).

Eur Urol Oncol. 2019 Jul;2(4):456-463. doi: 10.1016/j.euo.2018.12.002. Epub 2018 Dec 24.

PMID:
31277783
18.

Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.

Mandel PC, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T.

Eur Urol Focus. 2019 Jun 6. pii: S2405-4569(19)30145-2. doi: 10.1016/j.euf.2019.05.008. [Epub ahead of print]

PMID:
31178293
19.

Robot-assisted Radical Prostatectomy-So Successful Because It Is Better or Better Because It Is So Successful?

Knipper S, Graefen M.

Eur Urol Oncol. 2018 Oct;1(5):361-363. doi: 10.1016/j.euo.2018.08.021. Epub 2018 Sep 15. No abstract available.

PMID:
31158074
20.

Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis.

Mazzone E, Mistretta FA, Knipper S, Palumbo C, Tian Z, Pecoraro A, Preisser F, Gallina A, Shariat SF, Saad F, Graefen M, Montorsi F, Briganti A, Karakiewicz PI.

BJU Int. 2019 May 30. doi: 10.1111/bju.14841. [Epub ahead of print]

PMID:
31144770
21.

Contemporary clinicopathological characteristics of pT0 prostate cancer at radical prostatectomy: A population-based study.

Knipper S, Tilki D, Mazzone E, Mistretta FA, Palumbo C, Pecoraro A, Tian Z, Briganti A, Saad F, Graefen M, Karakiewicz PI.

Urol Oncol. 2019 Oct;37(10):696-701. doi: 10.1016/j.urolonc.2019.05.001. Epub 2019 May 22.

PMID:
31129038
22.

Minimal-Invasive Robot-Assisted Image-Guided Resection of Prostate-Specific Membrane Antigen-Positive Lymph Nodes in Recurrent Prostate Cancer.

van Leeuwen FWB, van Oosterom MN, Meershoek P, van Leeuwen PJ, Berliner C, van der Poel HG, Graefen M, Maurer T.

Clin Nucl Med. 2019 Jul;44(7):580-581. doi: 10.1097/RLU.0000000000002600.

PMID:
31107740
23.

Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study.

Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, Shariat SF, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Urol Oncol. 2019 Oct;37(10):702-710. doi: 10.1016/j.urolonc.2019.04.023. Epub 2019 May 15.

PMID:
31103337
24.

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.

Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Eur Urol Oncol. 2018 Aug;1(3):215-222. doi: 10.1016/j.euo.2018.03.007. Epub 2018 May 15.

PMID:
31102624
25.

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.

Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz P.

Eur Urol Oncol. 2018 Sep;1(4):314-320. doi: 10.1016/j.euo.2018.04.013. Epub 2018 May 15.

PMID:
31100253
26.

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.

Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Saad F, Pompe RS, Briganti A, Budäus L, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Oncol. 2018 Jun;1(2):160-168. doi: 10.1016/j.euo.2018.03.006. Epub 2018 May 15.

PMID:
31100241
27.

Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study.

Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, Briganti A, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Jun;17(3):231-237.e2. doi: 10.1016/j.clgc.2019.04.009. Epub 2019 Apr 16.

PMID:
31080021
28.

Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.

Klippenstein P, Schlomm T, von Amsberg G, Beyer B, Pompe RS, Michl U, Salomon G, Thederan I, Budäus L, Heinzer H, Tilki D, Haese A, Huland H, Graefen M, Steuber T, Tennstedt P.

Urol Oncol. 2019 Sep;37(9):575.e1-575.e7. doi: 10.1016/j.urolonc.2019.04.007. Epub 2019 Apr 30.

PMID:
31047783
29.

SNW1 is a prognostic biomarker in prostate cancer.

Höflmayer D, Willich C, Hube-Magg C, Simon R, Lang D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Huland H, Graefen M, Haese A, Heinzer H, Minner S, Büscheck F, Sauter G, Schlomm T, Steurer S, Clauditz TS, Burandt E, Wilczak W, Bernreuther C.

Diagn Pathol. 2019 May 1;14(1):33. doi: 10.1186/s13000-019-0810-8.

30.

External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort.

Tilki D, Preisser F, Graefen M, Huland H, Pompe RS.

Eur Urol. 2019 Jun;75(6):896-900. doi: 10.1016/j.eururo.2019.03.016. Epub 2019 Apr 5.

PMID:
30955970
31.

Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men ≤ 45 years of age.

Tilki D, Maurer V, Pompe RS, Chun FK, Preisser F, Haese A, Graefen M, Huland H, Mandel P.

World J Urol. 2019 Apr 2. doi: 10.1007/s00345-019-02740-8. [Epub ahead of print]

PMID:
30937571
32.

Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States.

Mazzone E, Mistretta FA, Knipper S, Tian Z, Larcher A, Widmer H, Zorn K, Capitanio U, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

J Endourol. 2019 Jun;33(6):438-447. doi: 10.1089/end.2018.0840.

PMID:
30931607
33.

A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures.

Haese A, Knipper S, Isbarn H, Heinzer H, Tilki D, Salomon G, Michl U, Steuber T, Budäus L, Maurer T, Tennstedt P, Huland H, Graefen M.

BJU Int. 2019 Jun;123(6):1031-1040. doi: 10.1111/bju.14760. Epub 2019 Apr 12.

PMID:
30927303
34.

Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center.

Preisser F, Theissen L, Wild P, Bartelt K, Kluth L, Köllermann J, Graefen M, Steuber T, Huland H, Tilki D, Roos F, Becker A, Chun FK, Mandel P.

Eur Urol Focus. 2019 Mar 21. pii: S2405-4569(19)30082-3. doi: 10.1016/j.euf.2019.03.007. [Epub ahead of print]

PMID:
30905598
35.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S.

Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1.

36.

Impact of the estimated blood loss during radical prostatectomy on functional outcomes.

Preisser F, Pompe RS, Salomon G, Rosenbaum C, Graefen M, Huland H, Karakiewicz PI, Tilki D.

Urol Oncol. 2019 May;37(5):298.e11-298.e17. doi: 10.1016/j.urolonc.2019.01.006. Epub 2019 Mar 8.

PMID:
30857988
37.

External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy.

Knipper S, Pröwrock D, Tian Z, Heinzer H, Tilki D, Karakiewicz P, Graefen M.

World J Urol. 2019 Mar 4. doi: 10.1007/s00345-019-02706-w. [Epub ahead of print]

PMID:
30830275
38.

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.

Schroeder C, Grell J, Hube-Magg C, Kluth M, Lang D, Simon R, Höflmayer D, Minner S, Burandt E, Clauditz TS, Büscheck F, Jacobsen F, Huland H, Graefen M, Schlomm T, Sauter G, Steurer S.

BMC Cancer. 2019 Mar 1;19(1):193. doi: 10.1186/s12885-019-5390-1.

39.

Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.

Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, Huland H, Tilki D.

Eur Urol. 2019 Jul;76(1):106-114. doi: 10.1016/j.eururo.2019.01.048. Epub 2019 Feb 14.

PMID:
30772034
40.

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment.

Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H.

World J Urol. 2019 Feb 6. doi: 10.1007/s00345-019-02668-z. [Epub ahead of print]

PMID:
30725166
41.

Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records.

Leyh-Bannurah SR, Tian Z, Karakiewicz PI, Wolffgang U, Sauter G, Fisch M, Pehrke D, Huland H, Graefen M, Budäus L.

JCO Clin Cancer Inform. 2018 Dec;2:1-9. doi: 10.1200/CCI.18.00080.

42.

Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer.

van Leeuwen FWB, Winter A, van Der Poel HG, Eiber M, Suardi N, Graefen M, Wawroschek F, Maurer T.

Nat Rev Urol. 2019 Mar;16(3):159-171. doi: 10.1038/s41585-018-0140-8. Review.

PMID:
30644446
43.

[Local treatment of the primary cancer in oligometastatic prostate cancer-the new standard of care?]

Knipper S, Graefen M.

Urologe A. 2019 Jan;58(1):49-50. doi: 10.1007/s00120-018-0842-9. German. No abstract available.

PMID:
30617529
44.

The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy.

Pompe RS, Krüger A, Preisser F, Karakiewicz PI, Michl U, Graefen M, Huland H, Tilki D.

Eur Urol Focus. 2018 Dec 31. pii: S2405-4569(18)30410-3. doi: 10.1016/j.euf.2018.12.008. [Epub ahead of print]

PMID:
30606686
45.

Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study.

Preisser F, Mazzone E, Nazzani S, Knipper S, Tian Z, Mandel P, Pompe R, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2018 Dec 26. pii: S2405-4569(18)30405-X. doi: 10.1016/j.euf.2018.12.006. [Epub ahead of print]

PMID:
30594487
46.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
47.

Upregulation of centromere protein F is linked to aggressive prostate cancers.

Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, Sauter G, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Luebke AM.

Cancer Manag Res. 2018 Nov 9;10:5491-5504. doi: 10.2147/CMAR.S165630. eCollection 2018.

48.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer.

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis MC, Lübke AM, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R.

Cancer Manag Res. 2018 Nov 19;10:5909-5917. doi: 10.2147/CMAR.S172637. eCollection 2018.

49.

Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes.

Leyh-Bannurah SR, Zaffuto E, Dell'Oglio P, Tian Z, Moschini M, Capitanio U, Briganti A, Montorsi F, Fisch M, Chun F, Kachanov M, Budäus L, Graefen M, Huland H, Karakiewicz PI.

Urol Int. 2019;102(1):51-59. doi: 10.1159/000495071. Epub 2018 Nov 27.

PMID:
30481764
50.

Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.

Tilki D, Chen MH, Wu J, Huland H, Graefen M, Braccioforte M, Moran BJ, D'Amico AV.

JAMA Oncol. 2019 Feb 1;5(2):213-220. doi: 10.1001/jamaoncol.2018.4836.

PMID:
30452521

Supplemental Content

Loading ...
Support Center